Moreover, tumor [11C]erlotinib uptake was shown to be higher in TKI-sensitive EGFRmut tumors as compared to tumors with a wild-type EGFR, indicating that PET and [11C]erlotinib may identify patients that are sensitive to erlotinib therapy [1]. This evidence concerns the gene EGFR and neoplasm.